genprowebdirectory
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Current Issue
    • Past Issues
    • Supplements
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
A password will be e-mailed to you.
Genetic Engineering & Biotechnology News GEN – Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News Genetic Engineering & Biotechnology News
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Current Issue
    • Past Issues
    • Supplements
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Home 2011

MDxHealth

Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy
Bioprocessing

Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy

GEN Staff Writer -
March 15, 2011
0

Recently Featured

Gateway Grants Pneumonia Access to Become Resistant to Antibiotics

Gateway Grants Pneumonia Access to Become Resistant to Antibiotics

Huntington’s Aggregates May Be Prevented by Chloroplast Enzyme

Huntington’s Aggregates May Be Prevented by Chloroplast Enzyme

Nobel Winner Katalin Karikó Shared mRNA Vaccine Story with <i>GEN</i>, Mid-Pandemic

Nobel Winner Katalin Karikó Shared mRNA Vaccine Story with GEN, Mid-Pandemic

ARPA-H’s First Industry Grant Sends $37M to Thymmune Therapeutics

ARPA-H’s First Industry Grant Sends $37M to Thymmune Therapeutics

Read the Digital Edition

August 2023 cover

Explore

  • About GEN
  • Contact GEN
  • GEN Staff
  • Editorial Guidelines
  • Reprints and Permissions
  • Scientific Advisory Board

Advertise

  • Media Kit and Planning Calendar
  • Advertising Terms and Conditions

Resources

  • Get the GEN Magazine
  • Get the GEN Email Newsletter
  • Inside Precision Medicine
  • Privacy Policy
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up